Table 2: Adjusted* means ± standard error (one-way analysis of covariance) of muscle mass and muscle strength according to low, medium, and high levels of inflammatory markers in male and female geriatric patients (GP).
Men |
||||||||||||
|
ALM (kg) n=32 |
P** |
ALM/h² (kg/m²) n=32 |
P** |
HGS (kg) n=32 |
P** |
LEP (W) n=31 |
P** |
Habitual GS (m/s) n=30 |
P** |
30 s STS test (n) n=30 |
P** |
hsCRP |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<0.98 mg/L) |
23.31 ± 1.00 |
|
7.46 ± 0.24 |
|
36.36 ± 2.17 |
|
178.7 ± 21.4 |
|
1.56 ± 0.19 |
|
12.61 ± 1.17 |
|
Medium (0.98-2.93 mg/L) |
23.13 ± 0.80 |
1.000 0.570 0.528 |
7.33 ± 0.19 |
1.000 0.892 1.000 |
36.35 ± 1.74 |
1.000 0.072 0.033 |
134.5 ± 16.9 |
0.355 0.391 1.000 |
1.29 ± 0.16 |
0.869 0.379 1.000 |
10.05 ± 0.94 |
0.308 0.091 1.000 |
High (>2.93 mg/L) |
21.56 ± 0.80 |
7.12 ± 0.19 |
29.63 ± 1.75 † |
134.1 ± 18.0 |
1.14 ± 0.17 |
8.95 ± 1.04 |
||||||
IL-6 |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<0.48 pg/ml) |
22.46 ± 0.82 |
|
7.10 ± 0.20 |
|
37.40 ± 1.84 |
|
179.7 ± 15.9 |
|
1.62 ± 0.15 |
|
11.39 ± 1.04 |
|
Medium (0.48-0.81 pg/ml) |
23.84 ± 0.93 |
0.785 1.000 0.398 |
7.44 ± 0.22 |
0.728 1.000 1.000 |
34.25 ± 2.08 |
0.763 0.035 0.301 |
114.6 ± 18.2 ‡ |
0.032 0.226 1.000 |
1.16 ± 0.17 |
0.136 0.099 1.000 |
9.26 ± 1.16 |
0.527 1.000 1.000 |
High (>0.81 pg/ml) |
21.63 ± 1.01 |
7.38 ± 0.24 |
28.82 ± 2.16 ‡ |
127.9 ± 20.6 |
1.04 ± 0.19 |
10.11 ± 1.30 |
||||||
TNF-α |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<14.17 pg/ml) |
21.27 ± 1.17 |
|
6.99 ± 0.28 |
|
36.04 ± 2.91 |
|
168.0 ± 25.9 |
|
1.56 ± 0.25 |
|
11.15 ± 1.65 |
|
Medium (14.17-20.10 pg/ml) |
21.91 ± 0.93 |
1.000 0.400 0.624 |
7.28 ± 0.22 |
1.000 0.729 1.000 |
32.30 ± 2.31 |
0.967 1.000 1.000 |
140.4 ± 20.6 |
1.000 1.000 1.000 |
1.37 ± 0.18 |
1.000 0.697 1.000 |
10.32 ± 1.19 |
1.000 1.000 1.000 |
High (>20.10 pg/ml) |
23.41 ± 0.68 |
7.39 ± 0.17 |
33.87 ± 1.70 |
140.44 ± 15.5 |
1.20 ± 0.14 |
10.15 ± 0.91 |
Women |
||||||||||||
|
ALM (kg) n=63 |
P** |
ALM/h² (kg/m²) n=63 |
P** |
HGS (kg) n=62 |
P** |
LEP (W) n=60 |
P** |
Habitual GS (m/s) n=61 |
P** |
30 s STS test (n) n=59 |
P** |
hsCRP |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<0.87 mg/L) |
17.54 ± 0.43 |
|
6.63 ± 0.12 |
|
22.65 ± 1.22 |
|
91.4 ± 11.7 |
|
1.22 ± 0.10 |
|
10.37 ± 1.03 |
|
Medium (0.87-2.05 mg/L) |
16.55 ± 0.52 |
0.432 0.283 1.000 |
6.55 ± 0.14 |
1.000 0.470 1.000 |
18.97 ± 1.45 |
0.162 0.016 1.000 |
66.1 ± 13.8 |
0.494 1.000 0.974 |
1.09 ± 0.12 |
1.000 0.330 1.000 |
10.28 ± 1.21 |
1.000 0.463 0.688 |
High (>2.05 mg/L) |
16.64 ± 0.31 |
6.42 ± 0.08 |
18.30 ± 0.85 ‡ |
82.6 ± 8.4 |
1.02 ± 0.07 |
8.56 ± 0.70 |
||||||
IL-6 |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<0.48 pg/ml) |
16.45 ± 0.30 |
|
6.49 ± 0.09 |
|
18.69 ± 0.90 |
|
79.76 ± 8.4 |
|
1.05 ± 0.07 |
|
9.55 ± 0.74 |
|
Medium (0.48-0.77 pg/ml) |
17.74 ± 0.52 |
0.116 0.748 0.930 |
6.59 ± 0.15 |
1.000 1.000 1.000 |
22.07 ± 1.52 |
0.192 1.000 0.548 |
87.7 ± 14.2 |
1.000 1.000 1.000 |
1.20 ± 0.13 |
0.946 1.000 1.000 |
8.75 ± 1.22 |
1.000 1.000 1.000 |
High (>0.77 pg/ml) |
17.05 ± 0.41 |
6.46 ± 0.12 |
19.39 ± 1.22 |
80.8 ± 12.0 |
1.09 ± 0.10 |
9.38 ± 1.00 |
||||||
TNF-α |
|
|
|
|
|
|
|
|
|
|
|
|
Low (<14.11 pg/ml) |
17.81 ± 0.53 |
|
6.57 ± 0.15 |
|
23.38 ± 1.48 |
|
98.95 ± 14.29 |
|
1.11 ± 0.13 |
|
9.78 ± 1.23 |
|
Medium (14.11-19.25 pg/ml) |
16.38 ± 0.43 |
0.122 0.297 1.000 |
6.42 ± 0.12 |
1.000 1.000 1.000 |
20.02 ± 1.21 |
0.252 0.010 0.606 |
73.59 ± 12.03 |
0.537 0.743 1.000 |
1.17 ± 0.10 |
1.000 1.000 0.921 |
9.74 ± 1.01 |
1.000 1.000 1.000 |
High (>19.25 pg/ml) |
16.79 ± 0.29 |
6.52 ± 0.08 |
18.13 ± 0.82 ‡ |
79.59 ± 8.05 |
1.04 ± 0.07 |
8.99 ± 0.72 |
*Adjusted for age and BMI, **P-values describing possible differences in muscle mass and strength between GP with Medium vs. Low inflammatory markers, High vs. Low inflammatory marker and High vs. Medium inflammatory marker are shown, †P < 0.05 vs. Medium, ‡P < 0.05 vs. Low